Loss of functional β-cell mass is the key mechanism leading to the two main forms of
diabetes mellitus—type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling
pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T …

Islets derived from stem cells hold promise as a therapy for insulin-dependent diabetes, but
there remain challenges towards achieving this goal,,,,–. Here we generate human islet-like …

Summary Type 1 diabetes (T1D) is widely considered to result from the autoimmune
destruction of insulin-producing β cells. This concept has been a central tenet for decades of …

Abstract Type 1 diabetes (T1D) is an autoimmune disease in which immune cells destroy
insulin-producing beta cells. The aetiology of this complex disease is dependent on the …

Objective To better define the rare adverse event (AE) of diabetes mellitus associated with
immune checkpoint inhibitors (ICIs). Design and methods We report the case of a lung …

Technological advancements in blood glucose monitoring and therapeutic insulin
administration have improved the quality of life for people with type 1 diabetes. However …

Immune checkpoint receptors such as programmed cell death protein 1 (PD-1), cytotoxic T-
lymphocyte associated protein 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), and T cell …

Adoptive immunotherapy with Tregs is a promising approach for preventing or treating type
1 diabetes. Islet antigen–specific Tregs have more potent therapeutic effects than polyclonal …

Autoimmune diabetes mellitus is a rare but significant side effect of treatment with immune
checkpoint inhibitors. Immune checkpoint inhibitor-induced diabetes mellitus (CPI-DM) is …